Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Acarix AB operates as a medical technology company which is engaged in developing diagnostic tests for cardiovascular diseases primarily in Europe, China, and the United States. Its main activities are to develop, produce and market a new cardiovascular diagnostic method and similar equipment for the same and related services. The company develops the CADScor acoustic device that is designed to be used by doctors to help assess patients' risk of coronary artery disease.
Malmo, SE-211 11, Sweden